UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celldex Therapeutics
In a report published Friday, Jefferies & Company reiterated its Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and slightly raised its price target from $6.00 to $7.00.
Jefferies noted, “CLDX released an incremental pipeline update w/ focus on more mature data from CDX-011 EMERGE trial scheduled for presentation at San Antonio Breast mtg on 12/8. We expect EMERGE dataset along w/ FDA end of PhII mtg at year-end should help to guide CDX-011's late-stage development strategy. We continue to maintain a Buy based on the company's pipeline potential.”
Celldex Therapeutics closed on Thursday at $5.60.
Latest Ratings for CLDX
|Nov 2016||Aegis Capital||Initiates Coverage On||Buy|
|Oct 2016||Brean Capital||Assumes||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.